Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 3
1996 4
1997 3
2003 2
2004 2
2005 2
2006 4
2007 2
2008 6
2009 2
2010 2
2011 4
2012 5
2013 6
2014 6
2015 6
2016 9
2017 9
2018 13
2019 13
2020 14
2021 21
2022 25
2023 27
2024 18
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. Among authors: stefanski a. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Jastreboff AM, et al. Among authors: stefanski a. N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Online ahead of print. N Engl J Med. 2024. PMID: 39536238
The Diagnosis and Treatment of Sjögren's Syndrome.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. Stefanski AL, et al. Dtsch Arztebl Int. 2017 May 26;114(20):354-361. doi: 10.3238/arztebl.2017.0354. Dtsch Arztebl Int. 2017. PMID: 28610655 Free PMC article. Review.
SLC6A1 variant pathogenicity, molecular function and phenotype: a genetic and clinical analysis.
Stefanski A, Pérez-Palma E, Brünger T, Montanucci L, Gati C, Klöckner C, Johannesen KM, Goodspeed K, Macnee M, Deng AT, Aledo-Serrano Á, Borovikov A, Kava M, Bouman AM, Hajianpour MJ, Pal DK, Engelen M, Hagebeuk EEO, Shinawi M, Heidlebaugh AR, Oetjens K, Hoffman TL, Striano P, Freed AS, Futtrup L, Balslev T, Abulí A, Danvoye L, Lederer D, Balci T, Nouri MN, Butler E, Drewes S, van Engelen K, Howell KB, Khoury J, May P, Trinidad M, Froelich S, Lemke JR, Tiller J, Freed AN, Kang JQ, Wuster A, Møller RS, Lal D. Stefanski A, et al. Brain. 2023 Dec 1;146(12):5198-5208. doi: 10.1093/brain/awad292. Brain. 2023. PMID: 37647852 Free PMC article.
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.
Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Griffin R, Stefanski A, Garvey WT. Hankosky ER, et al. Among authors: stefanski a. Diabetes Obes Metab. 2024 Jan;26(1):319-328. doi: 10.1111/dom.15318. Epub 2023 Nov 6. Diabetes Obes Metab. 2024. PMID: 37932236 Clinical Trial.
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, Hemmingway A, Ahmad NN, Bunck MC, Stefanski A. de Lemos JA, et al. Among authors: stefanski a. Hypertension. 2024 Apr;81(4):e41-e43. doi: 10.1161/HYPERTENSIONAHA.123.22022. Epub 2024 Feb 5. Hypertension. 2024. PMID: 38314555 Free PMC article. No abstract available.
192 results